Notice Regarding UBIC's Termination of Basic Agreement on

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Notice Regarding UBIC's Termination of Basic Agreement on Acquisition of Shares through Third-party Allocation of Shares ("STEP 2014 Model" Straight-equity Issue Program), Acquisition of Share Warrants (10th Share Warrants) and Withdrawal of Securities Registration Statement

TOKYO, Dec. 19, 2014 (GLOBE NEWSWIRE) -- In connection with the share issuance program through a third-party allocation of its shares to the London Branch of Deutsche Bank (the "Purchaser") (the "Program") that was resolved by a meeting of the Board of Directors of UBIC, Inc. (the "Company") held on August 28, 2014 and announced on the same day in UBIC's press release entitled, "Notice of Conclusion of Basic Agreement on Acquisition of Shares through Third-party Allocation of Shares ("STEP 2014 Model" Straight-equity Issue Program) and Issue of New Shares and 10th Share Warrants Through A Third-party Allocation of Shares and Conclusion of Share Warrants Purchase Agreement (Additional Issuance Options)", the Board of Directors today resolved to terminate the Basic Agreement on Acquisition of Shares dated August 28, 2014 between the Company and the Purchaser (the "Agreement") and to acquire the 10th Share Warrants (the "Share Warrants") from the Purchaser. Further, the Company delivered to the Purchaser a termination notice of the Agreement and also withdrew a securities registration statement regarding the Fourth Issuance of New Shares that was filed with a Chief of the Kanto Local Financial Bureau today. Accordingly, the Company makes the following announcement.

Particulars

1.   Reasons for Termination of the Agreement and Acquisition of the Share Warrants

The main purposes of the Program were to raise the funds necessary for establishment of capital ties and business alliances, and mergers and acquisitions (collectively, "M&A"). While the Company had preliminary negotiations with several potential M&A targets after the acquisition of TechLaw Solutions Inc. in August 2014, the Company does not currently expect to reach consummate M&A with any potential target. The Company continues to evaluate several potential targets for M&A. Further, the necessity of raising new funds for R&D expenses in connection with M&A and other working capital needs is expected to diminish in the near term. While the Program anticipated that the Board of the Directors of the Company would resolve the necessity of the fourth issuance of the new shares on February 18, 2015, the Company believes that it is unlikely to need to raise new funds under the Program by that date.

While the Company will proceed with business alliances and M&A activities for business expansion and R&D activities in various areas, including medical and patent areas — and considering that there is strong probability that any potential M&A projects will not be closed in this fiscal year and that the Company enjoys an improvement in its overall financial condition — the Company and the Board believes that the desirability of the forth issuance of the new shares under the Program is low and the Board has resolved to terminate the Agreement.

Since the necessity of funds to be raised by the Share Warrants as part of the Program is also low, the Board also resolved to acquire the Share Warrants from the Purchaser.

2.     Details of Share Warrants

   
1. Name of share warrants UBIC, Inc. 10th Share Warrants
2. Number of share warrants to be acquired (type and total number of shares subject to share warrants) 1,000,000 share warrants (1,000,000 shares of UBIC common stock)
3. Purchase price JPY 1,570,000 (JPY 1.57 per share warrant)
4. Person from whom share warrants are acquired London Branch of Deutsche Bank
5. Scheduled date of acquisition January 19, 2015
6. Plan after acquisition By the resolution of the Board of Directors, the Company plans to cancel all the Share Warrants acquired.

3.     Results of Fund Raising under the Program and Uses of Funds

The Program consisted of up to four new issuances of 1,000,000 shares per issuance (as a general rule) of UBIC common stock and the concurrent issuance of share warrants by which 1,000,000 shares of UBIC common stock were able to be acquired. The initial expected total amount of funds to be raised under the Program was approximately JPY 5,870 million.

The number of Company shares under this Program was 1 million upon the 1st issuance. The total amount of funds actually raised under the Program was JPY 1,148 million. The followings are the details of the funds raised. Please note that the total paid-in amount of the Share Warrants (JPY 1,570 thousand) is referred to net balance deducted the purchase price.

    (Unit: thousand yen)
Items Initial Expected Amounts of
Funds to be Raised
(Approximate Net Balance)
Amounts of Funds
Actually Raised
(Approximate Net Balance)
1. Funds raised through new shares and Share Warrants 5,907,970 1,155,600
 Total paid-in amount of new shares 4,622,400 1,155,600
 Total paid-in amount of Share Warrants 1,570 0*
 Amount of assets invested in through exercise of Share Warrants 1,284,000 0
2. Estimated amount of issue fees borne by Company 38,000 7,600
3. Approximate net balance 5,869,970 1,148,000
* Please note that the Company is to pay the Purchaser for JPY 1,570 thousand to purchase the Share Warrants. This JPY 0 is the net balance with respect to the Share Warrants. 

Further, the followings are the details of uses of funds:

(Initially Expected Use)   (Unit: million yen)
Purposes of Use Initially Expected Amount to be used Planned Expenditure Period
1. Capital for overseas and domestic business expansion (M&As, business alliances) 4,400 (1,100 of 4,400 through Share Warrants) September, 2014 to March, 2016
2. R&D expenses 670 (178 of 670 through Share Warrants) September, 2014 to March, 2016
3. Other working capital 800 September, 2014 to March, 2017  
     
(Actual Use)   (Unit: million yen)
Purposes of Use Actual Amount to be used Expenditure
1. Capital for overseas and domestic business expansion (M&A, business alliances) 979 September, 2014  
2. R&D expenses 30  September, 2014 to November, 2014 
3. Other working capital 139 September, 2014 to November, 2014 

The funds actually raised were mainly used for the acquisition of the shares of TechLaw Solutions, Inc. as the Company's subsidiary as well as R&D expenses and other working capital. Following the acquisition of TechLaw Solutions, Inc., which is a long-established discovery vendor, the Company's base in the U.S. has been strengthened and the Company is rapidly proceeding with preparation of supplying the market with its services and products using cutting-edge technology.

4.     Future outlook  

While the Company had preliminary negotiations with several potential M&A candidates after the acquisition of TechLaw Solutions, Inc. in August 2014, the Company does not currently expect to reach consummate M&A with any potential target. The Company will continue to pursue business alliances and M&A activities for business expansion.

(For your information)

Summary of the Fourth Issuance of New Shares cancelled due to the termination of the Agreement.

1. New Shares issued UBIC common stock
2. Number of shares issued 1,000,000 shares
3. Issue price TBD (The issue price per share of new stock was planned to be 90% of the closing price of UBIC common stock on the Tokyo Stock Exchange on February 17, 2015.)
4. Total amount of issue price TBD
5. Amount credited to equity TBD
6. Deadline for application March 6, 2015
7. Payment date March 6, 2015
8. Delivery date of new shares March 6, 2015
9. Planned purchaser and number of shares London Branch of Deutsche Bank, 1,000,000 shares
10. Matters related to agreement on continued holding of New Shares etc. No agreement has been concluded with the purchaser on the continued holding or depositing of New Shares allocated.
However, UBIC has obtained purchaser's consent to report promptly to UBIC in writing information including name and address of the buyer(s), the number of shares sold, date of sale, price of sale, reason for sale, and method(s) of sale in the event it sells all or part of the New Shares allocated to it within two years since the effective date of the issuance of allocated shares (March 6, 2017).
11. Each of the above items is conditional on the relevant notice taking effect pursuant to the Financial Instruments and Exchange Act.

This document has been translated from the original Japanese-language document for reference purposes only. If there are any differences or discrepancies between the original Japanese-language document and this English translation, the original Japanese-language document shall supersede this English translation.

About UBIC

UBIC, Inc. (Nasdaq: UBIC ) (TSE: 2158 ) is a leading provider of e-discovery and digital forensic services for Asia and the world. UBIC has extensive experience working with electronically stored information composed in Chinese, Japanese and Korean (CJK) languages and utilizes that expertise for clients involved in cross-border litigation, corporate investigations, intellectual property disputes and much more. At the forefront of e-discovery innovation, UBIC's proprietary Lit i View® platform is moving the industry from "fact discovery" to "future discovery" by allowing clients to analyze e-mail messages and digital communications found in big data to reveal patterns in human thought and behavior.

For more information about UBIC, contact usinfo@ubicna.com or visit http://www.ubicna.com .

Safe Harbor Statement

This announcement contains forward-looking statements. These forward-looking statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the amount of data that UBIC expects to manage this year and the potential uses for UBIC's new service in intellectual property-related litigation, contain forward-looking statements. UBIC may also make written or oral forward-looking statements in its reports filed with, or furnished to, the U.S. Securities and Exchange Commission, in its annual reports to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about UBIC's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: UBIC's goals and strategies; UBIC's expansion plans; the expected growth of the data center services market; expectations regarding demand for, and market acceptance of, UBIC's services; UBIC's expectations regarding keeping and strengthening its relationships with customers; UBIC's plans to invest in research and development to enhance its solution and service offerings; and general economic and business conditions in the regions where UBIC provides solutions and services. Further information regarding these and other risks is included in UBIC's reports filed with, or furnished to the Securities and Exchange Commission. UBIC does not undertake any obligation to update any forward-looking statement, except as required under applicable law. All information provided in this press release and in the attachments is as of the date of this press release, and UBIC undertakes no duty to update such information, except as required under applicable law.

CEO and Chairman of the Board Masahiro Morimoto Address any inquiries to Chief Financial Officer and Chief Administrative Officer Masami Yaguchi Tel. 81-3-5463-6344

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Gaine Expands Healthcare Data Solutions Ahead of HLTH 2026

Updated Category News Views 184

Ever felt like healthcare systems are still stuck in a bygone era, struggling with data flinging through the void? Well, Gaine Technology is throwing down its gauntlet to change that narrative. Successful in pharmaceuticals and life sciences, they're turbocharging their Consent and Preference Management solution across the vast, tangled web of healthcare markets just in...

Continue Reading
Innovent's Seven Drugs Leap onto 2026 Reimbursement Chart

Updated Category News Views 223

A Bold Move in Biopharmaceuticals Innovent Biologics just pulled a rabbit out of their hat. Seven of their cutting-edge meds made it onto China's National Reimbursement Drug List for 2026. This isn't just a spreadsheet entry—it's a lifeline thrown to patients across the oncology, metabolic, and autoimmune landscapes, as well as a financial booster for Innovent (HKEX:...

Continue Reading
El Pollo Loco Faces Class Action Over Wage Practices

Updated Category News Views 222

Alright, here's where things start sizzling—El Pollo Loco, the fast-food chicken chain whose name translates to 'The Crazy Chicken'—is in a legal pickle. The lawsuit hanging over their heads could spell a sticky situation for them and possibly ripple through the fast-food industry. The suit, filed by the steadfast firm Blumenthal Nordrehaug Bhowmik De Blouw LLP, has...

Continue Reading
HiTHIUM Joins Cambridge to Boost Global Energy Storage

Updated Category News Views 341

HiTHIUM and Cambridge's New Energy Venture There's a big splash coming out of Xiamen, folks. HiTHIUM, a heavyweight in the energy storage sector, has decided to team up with the University of Cambridge. They inked a deal aiming to bridge the academic ivory tower with industrial grit, focusing on long-duration energy storage. It was all sealed during the Global Energy...

Continue Reading
Ecopetrol Sidesteps Hefty Fines After Investigation Closure

Updated Category News Views 174

Colombian Watchdog Gives Ecopetrol a Pass It's like dodging a bullet in a duel at high noon. The Superintendency of Industry and Commerce (SIC) has finally closed its investigation into Ecopetrol S.A. and its subsidiaries, CENIT and OCENSA, after a probe two years in the making. The stakes were sky-high, folks. We're talkin' about just shy of 530 billion Colombian pesos...

Continue Reading
Webull Faces Class Action: Key Details for Investors

Updated Category News Views 136

What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...

Continue Reading
Greenberg Traurig's Brad Kaufman: A Mentor of Resolute Impact

Updated Category News Views 300

A Milestone for Mentorship at Greenberg Traurig In the often cutthroat jungle of law, finding someone who actually gives a damn about you is as rare as finding a unicorn. Yet, there it is—Brad Kaufman, at the helm of Greenberg Traurig's professional development, proving that mentorship can be more than just a checkbox on a quarterly review. Award for Exceptional...

Continue Reading
Fluence Energy Faces Leadership Departures Amid Legal Woes

Updated Category News Views 106

Fluence Energy's Rocky Road Continues It's chaos once again in the halls of Fluence Energy (NASDAQ:FLNC). The ship seems to drift further from solid ground as their CEO and CFO candidly decided to jump ship, shaking investor confidence even more vigorously. The market's reaction was swift and brutal: a nasty 9% share drop, leaving investors with more than just a headache....

Continue Reading
CARsgen's CAR-T Breakthrough on China's Insurance List

Updated Category News Views 136

A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...

Continue Reading
AppLovin Legal Woes: A Deep Dive into Investor Claims

Updated Category News Views 153

AppLovin Faces Legal Heat and Market Scrutiny Bitter truth has a way of crashing like a wave, and AppLovin (NASDAQ: APP) is feeling the brunt of it. Now knee-deep in a securities class action, the firm’s been accused of selling fairy tales about its AI capabilities, leaving investors clutching at substantial losses. If you’ve been banking on their promises between...

Continue Reading

Top 5 Most Recently Viewed Articles

CJ BIO's Bold Steps for Sustainable Animal Nutrition

Updated Category News Views 558

Breaking New Ground in Animal Nutrition Picture this: industry big wigs and farmers alike, all rubbing elbows at EuroTier 2026, the grand meeting ground for animal nutrition's future. This is where CJ BIO is flexing its muscles, not by just tossing ingredients into the mix, but by revolutionizing them under the banner "Feed Intelligence for Sustainable Performance." Now,...

Continue Reading
ParaZero Technologies Achieves Nasdaq Compliance Milestone

Updated Category News Views 130

ParaZero Technologies Regains Compliance with Nasdaq Standards Recent developments in the aerospace sector have highlighted the impressive strides made by ParaZero Technologies Ltd. (Nasdaq: PRZO), an innovator in safety systems for drones and urban air mobility vehicles. The company has reached a significant milestone, regaining compliance with Nasdaq’s minimum bid...

Continue Reading
Revolutionizing Semiconductor Design with AI Integration

Updated Category News Views 389

Ricursive Intelligence Launches Groundbreaking AI Lab Ricursive Intelligence is setting a new standard in semiconductor design with the introduction of its innovative AI lab. This initiative aims to seamlessly blend artificial intelligence with chip creation to expedite progress within the tech landscape. Major Funding and Valuation Boost The company recently raised an...

Continue Reading
Craneware plc Publishes a Key Trading Disclosure Notice

Updated Category News Views 219

Introduction to Craneware plc's Trading Disclosure Craneware plc, a prominent player in the healthcare technology space, has officially announced a significant trading disclosure following the rules established in the Takeover Code. This notification serves as an important communication to stakeholders about recent trading activities that involve exempt principal traders...

Continue Reading
Stocks to Consider Amidst Global Market Uncertainty

Updated Category News Views 150

The Current Market Landscape As geopolitical tensions rise, markets are experiencing undercurrents of uncertainty. Recent tariff threats have sent ripples through global financial markets, particularly affecting investor confidence in stocks. The atmosphere is becoming increasingly cautious, with many investors wondering which stocks might shield their portfolios during...

Continue Reading